Bax agonist 1 (compound SMBA2) is used in the study of lung cancer by acting as a Bax agonist (Ki = 57.2 nM); it induces conformational changes in Bax by blocking S184 phosphorylation, promoting Bax insertion into the mitochondrial membrane and oligomerization, thereby triggering cytochrome c release and apoptosis in Bax-expressing malignant cancer cells.